Benefits of Psychoactives Has a Big Name Billionaire Backing This Startup

Learn Why Optimi’s (CSE:OPTI) (OTCQX:OPTHF) Built to Supply All of the Companies Wanting to Get Into This Multi-Billion Dollar Industry

If you think for one second that the psychoactive movement taking place right now is just “hype,” think again. 


Because, unlike the psychoactive movement of the 60s, which conjures up images of tie-dye T-shirts and peace signs, the current psychoactive renaissance is fueled by science, governments, celebrities and big-time investors.

From Time magazine founder Henry Luce1  to entertainers like Sting2 and Kristen Bell3 to elite athletes like boxer Mike Tyson4  and former NHL star Mark Messier,5 and even one of the NFL’s top quarterbacks, Aaron Rodgers,6 celebrities and prominent influencers are touting the many benefits of psychoactives.

Even streaming giant Netflix continuously features psychoactive documentaries that further push the idea of hallucinogenics as medicine into the mainstream.

And the latest documentary, “How to Change Your Mind” by best-selling author and journalist Michael Pollan has effectively tipped the scales in favor of psychoactive medicine.7 

Gone are the days when magic mushrooms and Molly were merely party favors with a bad rep. 

Their potential to save lives is so evident that even President Joe Biden expected regulators to approve Molly and psilocybin within the next two years to treat PTSD and depression.8 

And smart investors are quickly catching onto the massive potential of this market.

Just look at the recent trading volume of stocks in the space. Like Mind Medicine, which experienced over 160 million in one day and shot up almost 50%.

Even one of the world’s best trend spotters, Chip Wilson,9, 10 founder of athleisure juggernaut Lululemon Athletica (NASDAQ:LULU) (market cap +US$40 billion), has turned his attention towards psychoactives.11  

But instead of following the hype surrounding stocks like MindMed (which may have been created by a 20-year-old USC student12), Wilson has uncovered a hidden gem that the rest of the market hasn’t caught wind of yet.

That company is called Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF).

Built to provide the backbone for psychoactive medicine developers in the West with the world’s largest EU-GMP compliant psilocybin cultivation facility is Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF). 

OPTI is already fully licensed with Health Canada and backed by a billionaire trend spotter who’s about to score another win.

Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) not only operates the world’s largest EU-GMP compliant psilocybin cultivation facility but it’s also built to supply ALL other companies that want to get into the psilocybin space. 

Why is psilocybin such a big deal? Well, science has just revealed that in the long run, SSRIs (mainstream antidepressants) do practically nothing to improve patients’ lives.13, 14 

Yet, psilocybin is showing promising results for treating depression, along with other mental health issues like anorexia,15 anxiety,16 cluster headaches,17 and obsessive-compulsive disorder.18

These magic mushrooms have been hitting nothing but home runs, showing effectiveness in major depression for up to a year for most patients.19 

They work… and they work well.

Source: NBC News

Functional mushrooms like lion’s mane and cordyceps are also gaining a following for their potential health benefits and are fully legal across the globe.

This is another bonus for Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF), which already has a line of functional mushroom products on the market and is gaining revenue.

By now, it should be evident to you that an exciting new trend is upon us.

When Chip Wilson saw yoga on the rise, did he invest in a chain of yoga studios? Heck no. 

He went for the proverbial picks and shovels play by outfitting the flocking crowd.

Today, Lululemon has nearly 600 stores around the world20 and is pulling in over $6.3 billion annually.21 

When you look at how profitable that venture was and still is, it’s easy to see why investors should pay attention to this man. 

Like Lululemon, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is another picks-and-shovels play that stands out. Optimi is a fully vertically integrated cultivation to consumer business meaning the company controls the entire supply chain.

Now, let’s break down the numerous reasons why Optimi Health is easily THE BEST WAY to get in on the wild world of magic mushrooms, as the functional fungi is poised to take the mental health industry by storm.

7 Reasons

Optimi Health (CSE:OPTI) (OTCQX:OPTHF) is a Primary Driver in the Mushroom Revolution


Fully Licensed by Health Canada: To date, Health Canada has only licensed 22 entities to produce psilocybin and synthetic psychoactive products, only a handful of which have the ability to actually supply the market. Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is approved to supply Canada’s Special Access Program (SAP) as well as Clinical Trials and is fully licensed to package and export products globally, with the know-how of its in-house distribution experts.


Full Vertical Integration / Cultivation to Consumer (CTC): Stacked with multi-revenue generating assets such as e-Commerce, farm, and lab facilities, Optimi Health is built for success, having already established international sales and growth opportunities with B2B relationships. This means that Optimi, which is ready to deliver products to patients, is the one-stop shop for ANY big psilocybin company looking to get products to market. If they want the ingredients, chances are highly likely they’ll need to go through Optimi to obtain them.


Largest EU-GMP compliant Psilocybin Cultivation Facility in the World: Already equipped with in-house Health Canada consulting, Optimi Health received its Health Canada Research Exemption in Jan 2021. The company later submitted for its Health Canada Dealers License Application for large-scale psilocybin cultivation at its TWO 10,000 sq ft GMP & EU GMP-capable facilities that house one of the sector’s largest genetic strains banks of psilocybin and functional mushrooms. OPTI has just received permission from Health Canada to manufacture and distribute other psychoactive substances, most notably Molly.22 The company also has room to expand, with +25 acres permitted and zoned for use to grow with increased market demand and regulation.


Well-Funded Revenue Runway: Through a very successful oversubscribed IPO, Optimi collected $20.7 million, that’s earmarked for financial investments that encompass the company’s capital expenditures for facilities, licensing, eCommerce platform buildout, strategic acquisitions, G&A, and other working capital. All the while, the company has prudently remained debt-free to date. Not to mention its large insider positions (which keep growing) and buying in the market.


Series of Supply Agreements and Partnerships: Not wasting any time, Optimi has amassed a string of deals, including supply agreements with Calgary-based Bloom Therapy and Research Centre23 and SABI Mind, a clinic group providing psychoactive-assisted therapies.24 The company is also preparing to supply many clinical trials around the world.


Steady Stream of R&D: Doing its part to move the entire sector ahead, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) has partnered up with multiple groups to advance R&D in the space, including signing an agreement with a University of Calgary incubator for review, design, planning and/or conducting clinical trial studies for future Optimi products; and applying for a second provisional patent for a unique proprietary two-part extraction and transdermal delivery process.


Exceptional Leadership with Strong Track Record of Success: Among its many professionals leading the way for Optimi, the most notable figure is billionaire founder of Lululemon (mkt cap $40B) sits on the advisory board.

Optimi: The Company Built to Supply All Other Players in the Space

Governments around the world are starting to embrace psychoactive medicine, including in the United States, where President Joe Biden’s administration anticipates regulators will approve treatments involving Molly and psilocybin25 within the next two years as designated breakthrough therapies for PTSD and Depression.26 

To the North, Canada has already begun to approve hallucinogens for treatment, which medical experts see as a very positive step.27 

All this means that there’s likely going to be a flood into the North American psilocybin space very soon, and the ones who already are established ahead of time will flourish.

With its world-class facility that’s up-to-code for internationally recognized standards and an in-house team specialized in global trade compliance, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is perfectly positioned to capitalize on this obviously-set-to-explode market.

In fact, Optimi has the unique opportunity to supply ALL of the major psychoactive medicine companies in the market—meaning: THIS COMPANY HAS NO TRUE COMPETITION.

By simply looking at its credentials, there’s no other company that can compare with the potential of Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF).

  • Fully licensed by Health Canada
  • Well-funded revenue pathway
  • The world’s LARGEST EU-GMP compliant psilocybin cultivation facility
  • Fully vertically integrated operation, built for cultivation to consumer (CTC)

While the market is clearly starting to give noticeable values to other companies in the psychoactive medicine space, Optimi Health (CSE:OPTI) (OTCQX:OPTHF) is supplying natural, EU-GMP psilocybin and synthetic psychoactives that ALL of the companies listed below would benefit from while conducting their own research in this fast-growing field.

To put it another way, if we were talking about the electric vehicles (EV) industry, Optimi would be the world’s largest lithium producer and in a position to supply all of the lithium batteries for the entire EV market.

“I think, generally, people should be open to psychoactives… A lot of people making laws are kind of from a different era, so I think, as the new generation gets into political power, I think we will see greater receptivity to the benefits of psychoactives.”37

Elon Musk, the World’s Richest Man

Targeting a MASSIVE Mental Health Market Opportunity

As can be seen in the chart above, while some of the large companies have been approved by regulators for trials, only Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is licensed to PRODUCE & DISTRIBUTE psilocybin in large-scale quantities for eventual commercial sales.

In order to continue their research, and to move forward toward the launch of new products, most of these industry giants will need a tier 1 ingredients supplier such as Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) to fulfill their supply needs, and to bring their formulations to market.

New investment is flooding into this space, attracting significant interest from the Venture Capitalist community. 

While in 2016, only 12 VC transactions were conducted in the psychoactive medicine space…, in 2021, that number nearly expanded FIVE-FOLD to 56.38 

For Optimi Health, the market opportunity goes FAR BEYOND just supplying others with medicinal ingredients.

Not only does Optimi’s opportunity involve cultivation, but the entire operation includes a very strong business model and a Vertically Integrated Operation that extends from Cultivation to Consumer (CTC), offering multiple revenue streams along the way.

Optimi Health’s (CSE:OPTI) (OTCQX:OPTHF) potential multi-revenue generating assets include:

  • E-Commerce
  • Farm and Lab Facilities
  • International sales and growth opportunities established through B2B relationships (more on this below!)

Important Market Statistics and Projections

The overall Global Mental Health Market is projected to skyrocket to more than US$527 billion by 2030.39 

The Global PTSD Treatment Market is valued at US$990.7 million, and is projected to grow at a CAGR of 4.2% through to 2028.40 

The Market for Treating Anxiety Disorders and Depression is set to grow to US$13 billion by 2027.41 

The Global Psychoactive Medicine Market is projected to reach US$6.4 billion by 2029.42 

The Largest, EU-GMP Compliant Psilocybin Cultivation Facility in the World

As we’ve already highlighted above, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) has the world’s largest EU-GMP compliant psilocybin cultivation facility, which is integral to the company’s story.

What exactly does this mean? Is bigger automatically better?

Well, in this case… YES. It is.

The first facility, Optimi Developmental, was designed as the first state-of-the-art pharmaceutical-grade operation and future global leading GMP certified producer and supplier of psilocybin mushrooms for the ever-growing psychoactive research and pharmaceutical industry.

The next facility, Optimi Functional, was designed specifically for CTC (Cultivation To Consumer), with an aim towards maximizing margin across the value chain with on-site extraction capabilities, new product innovation, packaging and ground-up production of high-demand functional mushroom varieties such as Lion’s Mane, Reishi, Turkey Tail, and Cordyceps.

Together, these make Optimi Health an absolute POWERHOUSE in the psilocybin & psychoactive industry. In February 2022, the company was approved for large-scale psilocybin cultivation, and on August 5th Optimi was granted  further approval by Health Canada to manufacture and distribute Molly and other synthetic psychoactives.43 

At its core, perhaps the biggest asset besides the brick and mortar infrastructure is the IP, as Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) has amassed one of the world’s largest genetic strain banks of psilocybin and functional mushrooms in the sector.44

While much of the talk so far has been around the potential for soon-to-be-legal psychoactive therapy products, there’s another important piece to the Optimi Health puzzle—functional mushroom products that are ALREADY legal.

Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) currently produces and sells a line of functional mushroom products, which fall under the rapidly growing market of nutraceuticals—foods containing health-giving additives and having medicinal benefits.

The Global Nutraceuticals Market is predicted to hit US$516.5 billion by 2028, growing at a CAGR of 7.6% along the way.45 

Within that group, the Global Functional Mushroom Market had a value of US$27.7 billion in 2021, and is expected to grow by a CAGR of 8.44% to US$52.3 billion by 2030.46 

By tapping into this market, OPTI is targeting more than just patients of therapists, but also the over-the-counter, wellness-seeking crowd. These products are legal all around the world and are becoming increasingly more and more popular. 

Having the ability to generate revenue from functional mushroom products further separates Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) from its solely-research-focused psychoactive medicine company counterparts.

Well-Funded Revenue Pathway with a STRONG Business Model

Excitement surrounding the potential for Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) has been red hot from the moment it started trading.

Early in 2021, in its Initial Public Offering (IPO), OPTI raised $20.7 million through an oversubscribed financing driven by co-founder JJ Wilson and his billionaire father, who’s famous for spotting huge trends before they explode.47 

Since then, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) has gone on to build upon this momentum more, by taking on many millions of dollars’ worth of orders—with a constant stream of new deals being announced all the time.

When looking at all that Optimi has delivered on from their prospectus over the last year and a half, this company has been hitting it out of the park.

Recent key catalysts include: Facilities (complete), First Grow (complete), First Sale (complete), First batch of psilocybin with the next batch at the end of August (already sold), and an Analytical Laboratory (complete). The company is currently growing one of the largest legal psilocybin harvests ever.

Today, Optimi is already generating revenue—all of which was achieved successfully and prudently with NO DEBT, while working towards a very feasible goal of cash neutrality, and eventually positive EBIDTA.

The company achieved this by building out the business on multiple fronts (functional and psilocybin mushrooms). 

So far, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) has amassed and signed a series of significant partnership and supply agreements. Each of these provides more opportunities for liquidity, while simultaneously increasing brand awareness and building up a respectable industry-wide reputation.

Among the more notable deals to date, have been:

  • A supply agreement with clinical-stage natural psychoactive medicine development company, Filament Health, for psilocybin mushrooms.48 
  • An exploratory supply agreement with ATMA Journey Centers, a psilocybin-assisted therapy and practitioner training services facilitator for palliative care and mental health.49 
  • Consulting services agreement with a University of Calgary business incubator for review, design, planning and/or conducting clinical trial studies for future Optimi products.
  • A supply agreement with Halucenex Life Sciences, a wholly owned subsidiary of Creso Pharma of Australia.50 

Exceptional Leadership Team

In order to deliver upon such high expectations in the mushrooms-as-medicine space, Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is built to succeed with world-class stewardship. Beyond its management team, Optimi’s being guided by incredible advisors, including Edward Safarik who is the former Founder, President and CEO of Ocean Fisheries Limited, celebrity fitness and nutrition specialist Harley Pasternak, and other outstanding minds. 

OPTI’s leadership team includes:

William (Bill) J. CiprickChief Executive Officer
Over 25 years of Global experience across a wide array of industries in multifunctional organizations ranging from Fortune 500 corporations to small and medium-sized businesses. Prior experience includes leading a specialty advisory practice for the Business Development Bank of Canada, running his own successful consulting firm and helping a high-tech company go public and grow from $200M to $800M in under 4 years. Ciprick additionally spent 17 years at Procter & Gamble and has a love and proven track record for growing products.
Bryan SafarikCOO & Director
Over 15 years of experience in Senior Management roles, as well as Founder and President of various profitable private companies. His experience includes serving as Director of Marine Operations at Ocean Fisheries LTD before the sale to the Jim Pattison group. Safarik also co-founded, and currently serves as President for BC Green Pharmaceuticals Inc.
Dane StevensCMO & Director
An entrepreneur with 15 years of experience in international product sourcing, development, manufacturing, and quality control, Stevens is the founder of multiple successful wholesale and retail DTC businesses and is currently President of Cavalier Jewellers LTD. After investing in several venture start-ups, he now concentrates his efforts on various philanthropic endeavours, and on the science-based benefits in the rapidly evolving world of fungi.
JJ WilsonCo-Founder, Chairman of the Board
Active CEO and Co-Founder of Ride Cycle Club and Partner at Very Polite Agency. Wilson’s previous experience includes leading the international expansion of Kit and Ace, in addition to developing the business’s brand, eCommerce, and retail. A recent graduate from Harvard Business School, Wilson now focuses on strategic growth initiatives and development for his operating companies, in addition to independent strategic investments, and philanthropy.
Jacob SafarikCo-Founder, CFO
Over 15 years of experience in accounting, project finance, business development and quality assurance. Prior experience includes playing a lead advisory role in the divestiture and sale of a $6 billion business in San Francisco. Safarik also worked in Vienna, Austria where he managed various audit and assurance engagements for key infrastructure and development initiatives funded by the European Union. He’s also a Co-Founder and Chief Financial Officer of BC Green Pharmaceuticals Inc.

RECAP: 7 Reasons

To Seriously Look Into  Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) NOW!


Fully Licensed by Health Canada


Full Vertical Integration / Cultivation to Consumer (CTC)


Largest EU-GMP compliant Psilocybin Cultivation Facility in the World


Well-Funded Revenue Runway


Series of Supply Agreements and Partnerships


Steady Stream of R&D


Exceptional Leadership with Strong Track Record of Success

With so many incredible products under development, the infrastructure and leadership in place to succeed, now is THIS IS THE PERFECT TIME for smart investors to seriously follow the ongoing Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) story.

OPTI has amassed an impressive portfolio while building out the world’s LARGEST EU-GMP-compliant psilocybin cultivation facility. 

This is a bonafide picks-and-shovels play in the rapidly expanding psychoactives space, all while also offering a full vertically integrated CTC business model.

You’re going to want to keep tabs on this future mushroom JUGGERNAUT by clicking here to visit their website and sign up for the company’s newsletter to make sure you don’t miss out on any of Optimi Health’s news and milestones.

Copyright 2022 Kong Media. All Rights Reserved | Privacy Policy | Disclaimer

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14],within%20six%20to%20eight%20weeks [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45]–growing-at-cagr-of-7-60-from-2021-2028-175-pages–says-research-dive-301590755.html [46] [47] [48] [49] [50]